MedTrace Logo

Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor

NCT03779399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-12-19

No results posted yet for this study

Summary

The aim of the study was to estimate the percentage and of Treg, Th17 and NKT in peripheral blood and the tissue of the epithelial ovarian tumor and relationship with blood serum level of HE4, CA125, as well as algorithm ROMA.

Material and methods Mononuclear cells (PBMCs) were isolated by density gradient centrifugation obtained from peripheral blood and ovarian tissue of patient suffering ovarian pathology. Patient from control group underwent surgery for unexplanied infertility. The percentage of Treg and Th17 , NKT in peripheral blood and the tissue was assessed using the flow cytometry method according to the manufacturer's instructions. The ROMA index was calculated according to the levels of HE4 and CA-125 in serum.

Conditions

  • Ovarian Cancer
  • Borderline Ovarian Tumors
  • Benign Ovarian Tumor
  • Unexplained Infertility

Interventions

OTHER

Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.

Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.

Sponsors & Collaborators

  • Medical University of Lublin

    lead OTHER

Principal Investigators

  • Izabela Winkler · Medical University of Lublin

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-01
Primary Completion
2014-05-31
Completion
2016-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03779399 on ClinicalTrials.gov